Quality management in clinical application of mass spectrometry measurement systems

Clinical Biochemistry

Volumn 49, Issue 13-14, 2016, Pages 947-954

  Vogeser, Michael ^a   Seger, Christoph ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Risch Laboratory Group   (Israel)

Author keywords

Evaluation; Mass spectrometry; Quality assurance; Quality management; Validation

Indexed keywords

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL LABORATORY; DIAGNOSTIC TEST; HUMAN; LABORATORY DIAGNOSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT ACCURACY; PATIENT CARE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY CONTROL; SOLID PHASE EXTRACTION; STANDARDIZATION; TANDEM MASS SPECTROMETRY; CALIBRATION; PROCEDURES; RISK MANAGEMENT; VALIDATION STUDY;

CALIBRATION; HUMANS; MASS SPECTROMETRY; QUALITY CONTROL; RISK MANAGEMENT;

EID: 84979609761     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.07.005     Document Type: Article

References (28)

1. [1] Balogh, E.P., Miller, B.T., Ball, J.R., Editors; Committee on Diagnostic Error in Health Care; Board on Health Care Services; Institute of Medicine; The National Academies of Sciences, Engineering, and Medicine. Improving diagnosis in healthcare, 2015 ISBN 978-0-309-37769-0.
2. [2] Singh, H., Graber, M.L., Improving diagnosis in health care – the next imperative for patient safety. N. Engl. J. Med. 373 (2015), 2493–2495.
3. [3] Rotmensch, S., Cole, L.A., False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 355:9205 (2000), 712–715.
4. [4] Bolstad, N., Warren, D.J., Nustad, K., Heterophilic antibody interference in immunometric assays. Best Pract. Res. Clin. Endocrinol. Metab. 27 (2013), 647–661.
5. [5] Garcia-Gonzales, E., Aramendia, M., Alvarez-Ballano, D., Trincado, P., Rello, L., Serum sample containing endogenous antibodies interfering with multiple hormone immunoasays. Laboratory strategies to detect interference. Pract. Lab. Med. 4 (2016), 1–10.
6. [6] Vogeser, M., Seger, C., Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin. Chem. 56 (2010), 1234–1244.
7. [7] Vogeser, M., Seger, C., A decade of HPLC-MS/MS in the routine clinical laboratory–goals for further developments. Clin. Biochem. 41 (2008), 649–662.
8. [8] Van den Ouweland, J.M.W., Kema, I.P., The role of liquid chromatography-tandem mass spectrometry in the clinical laboratory. J. Chromatogr. B 883-884 (2012), 18–32.
9. [9] Grant, R.P., The march of the masses. Clin. Chem. 59 (2013), 871–873.
10. [10] Annesley, T., Diamandis, E., Bachmann, L., Hanash, S., Hart, B., Javahaery, R., Singh, R., Smith, R., A spectrum of views on clinical mass spectrometry. Clin. Chem. 62 (2016), 30–36.
11. [11] Annesley, T.M., Cooks, R.G., Herold, D.A., Hoofnagle, A.N., Clinical mass spectrometry-achieving prominence in laboratory medicine. Clin. Chem. 62 (2016), 1–3.
12. [12] Jannetto, P.J., Fitzgerald, R.L., Effective use of mass spectrometry in the clinical laboratory. Clin. Chem. 62 (2016), 92–98.
13. [13] Vogeser, M., Seger, C., Mass spectrometry methods in clinical diagnostics – state of the art and perspectives. Trends Anal. Chem., 2016, 10.1016/j.trac.2016.04.018 (in press).
14. [14] Christians, U., Vinks, A.A., Langman, L.J., Clarke, W., Wallemacq, P., van Gelder, T., Renjen, V., Marquet, P., Meyer, E.J., Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs. Ther. Drug Monit. 37 (2015), 718–724.
15. [15] Kadian, N., Raju, K.S., Rashid, M., Malik, M.Y., Taneja, I., Wahajuddin, M., Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J. Pharm. Biomed. Anal. 126 (2016), 83–97.
16. [16] Clinical and Laboratory Standards Institute, C50-A. Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guidelines. 2007 (ISSN 0273–3099).
17. [17] Clinical and Laboratory Standards Institute, C62-A. Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline. 2014 (ISSN 1558–6502).
18. [18] Lynch, K.L., CLSI C62-A: a new standard for clinical mass spectrometry. Clin. Chem. 62 (2016), 24–29.
19. [19] Maier, B., Vogeser, M., Target analyte quantification by isotope dilution LC-MS/MS directly referring to internal standard concentrations - validation for serum cortisol measurement. Clin. Chem. Lab. Med. 51 (2013), 833–837.
20. [20] Shipkova, M., Vogeser, M., Ramos, P.A., Verstraete, A.G., Orth, M., Schneider, C., Wallemacq, P., Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Clin. Biochem. 47 (2014), 1069–1077.
21. [21] König, K., Kobold, U., Fink, G., Leinenbach, A., Dülffer, T., Thiele, R., Zander, J., Vogeser, M., Quantification of vancomycin in human serum by LC-MS/MS. Clin. Chem. Lab. Med. 51 (2013), 1761–1769.
22. [22] U.S. Department of Health and Human Services Food and Drug Administration (FDA), Center for Drug Evaluation and Research, www.fda.gov, 2001.
23. [23] ICH harmonised tripartite guideline. Validation of analytical procedures: Text and methodology, 2005 ( www.ich.org/products/guidelines.html).
24. [24] European Medicines Agengy (EMA), Guideline on bioanalytical method validation. www.ema.europa.eu, 2011.
25. [25] Scientific Working Group for Forensic Toxicology (SWGTOX) - standard practices for method validation in forensic toxicology. www.swgtox.org/documents/Validation3.pdf, 2013.
26. [26] Baldelli, S., Cattaneo, D., Fucile, S., Clementi, E., Lights and shadows of the actual European guidelines on bioanalytical method validation: the case of raltegravir. Ther. Drug Monit. 36 (2014), 739–745.
27. [27] Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75 (2003), 3019–3030.
28. [28] Twentyman, J.M., Cradic, K.W., Singh, R.J., Grebe, S.K., Ionic cross talk can lead to overestimation of 3-methoxytyramine during quantification of metanephrines by mass spectrometry. Clin. Chem. 58 (2012), 1156–1158.